Henry Schein, Inc. HSIC
87.42 USD -1.00 (-1.13%)
Nov 12, 2026, 12:32 PM EST
87.38 Day range 89.17
68.99 52-week range 90.86
- YTD
- +15.67%
- 1 year
- +20.02%
News
businesswire.com CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration BOSTON & MELVILLE, N.Y.--(BUSINESS WIRE)--CareQuest Institute and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration.
zacks.com Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think "Yes" Henry Schein (HSIC) possesses solid growth attributes, which could help it handily outperform the market.
zacks.com Henry Schein (HSIC) Upgraded to Buy: What Does It Mean for the Stock? Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com HSIC vs. MMSI: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Merit Medical (MMSI). But which of these two stocks presents investors with the…
zacks.com Here's Why Henry Schein (HSIC) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com Is Henry Schein (HSIC) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
businesswire.com Henry Schein to Participate in Upcoming Investor Conferences in November and December MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the…
benzinga.com UBS Maintains Neutral on Henry Schein, Raises Price Target to $95 UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $94 to $95.
benzinga.com Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $100 Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperform and lowers the price target from $105 to $100.
benzinga.com Henry Schein Sees Pressure From Discretionary Dental Delays Henry Schein drops after Q3 results: an EPS beat and raised 2026 guidance are offset by softness in discretionary dental procedures.
benzinga.com Henry Schein Q3 2026 Earnings Call Transcript Henry Schein (NASDAQ:HSIC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Henry Schein Raises FY2026 Adj EPS Guidance from $5.29-$5.39 to $5.50-$5.56 vs $5.39 Est; Affirms FY2026 Sales Guidance of $13.794B-$13.926B vs $13.866B Est Henry Schein (NASDAQ:HSIC) raises FY2026 Adj EPS guidance from $5.29-$5.39 to $5.50-$5.56 vs $5.39 analyst estimate. Affirms FY2026 sales outlook from $13.794 billion-$13.926 billion to $13.794…
benzinga.com Henry Schein Q3 Adj. EPS $1.56 Beats $1.36 Estimate, Sales $3.471B Miss $3.476B Estimate Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $1.36 by 14.71 percent. This is a 13.04 percent increase over earnings of $1.38…
benzinga.com Leerink Partners Maintains Market Perform on Henry Schein, Lowers Price Target to $92 Leerink Partners analyst Michael Cherny maintains Henry Schein (NASDAQ:HSIC) with a Market Perform and lowers the price target from $96 to $92.
benzinga.com Transcript: Henry Schein Q2 2026 Earnings Conference Call Henry Schein (NASDAQ:HSIC) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares…
benzinga.com Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor…
benzinga.com BTIG Maintains Buy on Henry Schein, Raises Price Target to $110 BTIG analyst David Larsen maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $110.- benzinga.com Barclays Maintains Overweight on Henry Schein, Raises Price Target to $100 Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $86 to $100.
benzinga.com UBS Maintains Neutral on Henry Schein, Raises Price Target to $94 UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $89 to $94.- benzinga.com Citigroup Maintains Buy on Henry Schein, Raises Price Target to $112 Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $112.
- benzinga.com Henry Schein Q2 2026 Earnings Call: Complete Transcript Henry Schein (NASDAQ:HSIC) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to…
benzinga.com Henry Schein Raises FY2026 Adj EPS Guidance from $5.23-$5.37 to $5.29-$5.39 vs $5.33 Est; Raises FY2026 Sales Guidance from $13.580B-$13.843B to $13.794B-$13.926B vs $13.738B Est Henry Schein (NASDAQ:HSIC) raises FY2026 Adj EPS guidance from $5.23-$5.37 to $5.29-$5.39 vs $5.33 analyst estimate. Raises FY2026 sales outlook from $13.580 billion-$13.843 billion to $13.794…
benzinga.com Henry Schein Q2 Adj. EPS $1.27 Beats $1.24 Estimate, Sales $3.458B Beat $3.375B Estimate Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.24 by 2.42 percent. This is a 15.45 percent increase over earnings of $1.10…- benzinga.com Piper Sandler Maintains Overweight on Henry Schein, Raises Price Target to $95 Piper Sandler analyst Jason Bednar maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $91 to $95.
- benzinga.com UBS Maintains Neutral on Henry Schein, Raises Price Target to $89 UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $85 to $89.
benzinga.com BMO Capital Initiates Coverage On Henry Schein with Market Perform Rating, Announces Price Target of $85 BMO Capital initiates coverage on Henry Schein (NASDAQ:HSIC) with a Market Perform rating and announces Price Target of $85.
benzinga.com This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page and analysts' views before buying MKTX stock.
benzinga.com This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on analyst ratings page. HSIC stock analysis.- benzinga.com BTIG Upgrades Henry Schein to Buy, Announces $100 Price Target BTIG analyst David Larsen upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Buy and announces $100 price target.
- benzinga.com Henry Schein Appoints William K. Daniel As Board Chairman, Effective Immediately Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected…
- benzinga.com UBS Maintains Neutral on Henry Schein, Lowers Price Target to $85 UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the price target from $87 to $85.
- benzinga.com Mizuho Maintains Neutral on Henry Schein, Lowers Price Target to $82 Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the price target from $88 to $82.
benzinga.com Transcript: Henry Schein Q1 2026 Earnings Conference Call 
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Henry Schein Affirms FY2026 Adj EPS Guidance of $5.23-$5.37 vs $5.32 Est; Affirms FY2026 Sales Guidance of $13.580B-$13.843B vs $13.717B Est Henry Schein (NASDAQ:HSIC) affirms FY2026 Adj EPS guidance from $5.23-$5.37 to $5.23-$5.37 vs $5.32 analyst estimate. Affirms FY2026 sales outlook from $13.580 billion-$13.843 billion to $13.580…
- benzinga.com Henry Schein Q1 Adj. EPS $1.32 Beats $1.22 Estimate, Sales $3.368B Beat $3.342B Estimate Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.22 by 8.2 percent. This is a 14.78 percent increase over earnings of $1.15…
- benzinga.com Morgan Stanley Maintains Underweight on Henry Schein, Raises Price Target to $64 Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and raises the price target from $61 to $64.
benzinga.com This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initiated Overweight rating on KALU with $170 PT.- benzinga.com Citigroup Initiates Coverage On Henry Schein with Buy Rating, Announces Price Target of $100 Citigroup analyst Daniel Grosslight initiates coverage on Henry Schein (NASDAQ:HSIC) with a Buy rating and announces Price Target of $100.
- benzinga.com Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $90 Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperform and lowers the price target from $100 to $90.
- benzinga.com Henry Schein Chairman Stanley M. Bergman to Retire After 44 Years, Board Shrinks to 10 Members Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced its plan to reduce the size of its Board of…
benzinga.com Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's…- benzinga.com Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $97 Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:HSIC) with a Outperform and raises the price target from $79 to $97.
- benzinga.com UBS Maintains Neutral on Henry Schein, Raises Price Target to $87 UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $79 to $87.
- benzinga.com JP Morgan Maintains Overweight on Henry Schein, Raises Price Target to $92 JP Morgan analyst John Stansel maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $78 to $92.
benzinga.com These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results - benzinga.com Mizuho Maintains Neutral on Henry Schein, Raises Price Target to $88 Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $81 to $88.
- benzinga.com Morgan Stanley Maintains Underweight on Henry Schein, Raises Price Target to $61 Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and raises the price target from $58 to $61.
- benzinga.com Wells Fargo Maintains Equal-Weight on Henry Schein, Raises Price Target to $87 Wells Fargo analyst Vik Chopra maintains Henry Schein (NASDAQ:HSIC) with a Equal-Weight and raises the price target from $76 to $87.